Last updated 8 months ago
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
825 patients around the world
Available in Spain, United States, Argentina
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency
in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.
Bellus Health Inc
13Research sites
825Patients around the world
Requirements for the patient
To 80 Years
All Gender
Medical requirements
Sites
Instituto del Buen Aire
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Instituto de Especialidades de la Salud Rosario Clínica del Tórax
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe
Instituto Médico Damic S.R.L.
Consultorios Médicos Dr. Isaac Scherbovsky - Mendoza
Instituto INSARES - Mendoza
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Mautalen - Salud e Investigación - CABA
StudyCALM-1
SponsorBellus Health Inc
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05599191
